Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does the dose matter?

W A Craig1

  • 1Department of Medicine, University of Wisconsin, Madison, WI, USA. wac@medicine.wisc.edu

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|August 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Antimicrobial agents and chemotherapy·2014
Same author

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

Antimicrobial agents and chemotherapy·2013
Same author

In vivo pharmacodynamics of new lipopeptide MX-2401.

Antimicrobial agents and chemotherapy·2010
Same author

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

Antimicrobial agents and chemotherapy·2008
Same author

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Antimicrobial agents and chemotherapy·2006
Same author

Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.

Antimicrobial agents and chemotherapy·2005
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Anticalcitonin: Limited utility of a context-dependent biomarker demonstrated in another real-world data set.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Procalcitonin Testing in Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Pharmacokinetic/pharmacodynamic (PK/PD) parameters are crucial for antibiotic efficacy. Understanding drug exposure like time above MIC and AUC/MIC ratios helps optimize dosing to combat infections and prevent resistance.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Pharmacokinetic/pharmacodynamic (PK/PD) parameters, including peak/MIC ratio, 24-h AUC/MIC ratio, and time above MIC, are vital for assessing drug-organism interactions.
  • Specific PK/PD targets are associated with the efficacy of different antibiotic classes.

Purpose of the Study:

  • To review the role of PK/PD parameters in predicting antibiotic efficacy and preventing antimicrobial resistance.
  • To highlight established PK/PD targets for key antibiotic classes and identify knowledge gaps.

Main Methods:

  • Literature review and synthesis of existing data on PK/PD parameter targets for various antibiotics.
  • Analysis of established PK/PD breakpoints for different drug classes and pathogens.

Related Experiment Videos

Main Results:

  • Time above MIC is critical for beta-lactams, macrolides, clindamycin, and linezolid, requiring 40%-50% of the dosing interval.
  • Peak/MIC ratios >8 and 24-h AUC/MIC ratios >100 are generally needed for aminoglycosides and fluoroquinolones against gram-negative bacilli.
  • Lower AUC/MIC ratios (25-35) may suffice for fluoroquinolones and azithromycin against pneumococci.

Conclusions:

  • PK/PD parameter optimization is essential for effective antibiotic therapy and resistance prevention.
  • Further research is needed to establish the clinical significance of mutation prevention concentrations and PK/PD targets for various antibiotic classes.